<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of group I metabotropic <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptors (mGluRs) in <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> is as yet unclear as mGluR1/5 antagonists and <z:chebi fb="4" ids="48705">agonists</z:chebi> yielded contradictory effects in different <z:e sem="disease" ids="C0684309" disease_type="Experimental Model of Disease" abbrv="">disease models</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we examined the neuroprotective potency of the selective mGluR5 <z:chebi fb="4" ids="48705">agonist</z:chebi>, (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG), in endothelin-1(ET-1)-induced focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>In addition to the effect of CHPG on the histologically defined <z:mpath ids='MPATH_124'>infarct</z:mpath> size, we studied its influence on sensorimotor impairments in the ladder rung walking test at late time points up to 4 weeks after the ischemic insult </plain></SENT>
<SENT sid="3" pm="."><plain>Rats were treated i.c.v. with an injection of 1mM CHPG beginning 10min after the application of ET-1 </plain></SENT>
<SENT sid="4" pm="."><plain>Histological analyses 4 weeks after ET-1-induced <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> demonstrated only a small, insignificant reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> size after CHPG application </plain></SENT>
<SENT sid="5" pm="."><plain>In accordance with this result, there were no significant effects of the used CHPG concentration on sensorimotor impairments in the ladder rung walking test </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, our data point to the restricted value of CHPG as a neuroprotectant after transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and to the importance of evaluating neuroprotective effects at late post-ischemic time points </plain></SENT>
</text></document>